Evaluation of baseline body-weight dosing of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Wiseman, G
Conti, P
Vo, K
Schilder, RJ
Foster, P
Gordon, LI
Emmanouilides, C
Silverman, D
Witzig, TE
Molina, A
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Univ So Calif, Dept Radiol, Los Angeles, CA 90089 USA
[3] Biogen Idec Inc, Global Med Affairs, San Diego, CA USA
[4] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[7] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA 90024 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2634
引用
收藏
页码：721A / 721A
页数：1
相关论文
共 50 条
  • [1] Radioimmunotherapy with 90Y Ibritumomab Tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Olivas, C.
    Bello, P.
    Vercher, J. L.
    Loaiza, J. L.
    Marti, J. F.
    Hervas, I.
    Rivas, A.
    Ruiz, C.
    Perez-Velasco, R.
    Mateo, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S419 - S419
  • [2] Radioimmunotherapy with 90Y Ibritumomab Tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Palumbo, B.
    Sabalich, I.
    Falcinelli, F.
    Capponi, M.
    Martelli, M.
    Palumbo, R.
    Sinzinger, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S419 - S419
  • [3] Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Wiseman, Gregory A.
    Conti, Peter S.
    Vo, Katie
    Schilder, Russell J.
    Gordon, Leo I.
    Emmanouilides, Christos
    Silverman, Dan H.
    Witzig, Thomas E.
    Darif, Mohamed
    Molina, Arturo
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (08): : 514 - 517
  • [4] Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma
    Witzig, TE
    SEMINARS IN ONCOLOGY, 2003, 30 (06) : 11 - 16
  • [5] Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin®) induces high response rates and durable remissions in patients with relapsed or refractory B-cell non hodgkin's lymphoma (NHL)
    Murray, JL
    Witzig, TE
    Molina, A
    Gordon, L
    Emmanouilides, C
    Vo, K
    Flinn, IW
    Czuczman, M
    Saville, W
    Wiseman, G
    White, CA
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S48 - S49
  • [6] Analysis of relationship between baseline body weight and efficacy/safety of yttrium 90 (90Y) ibritumomab tiuxetan radioimmunotherapy in patients (pts) with non-Hodgkin's lymphoma
    Wiseman, GA
    Emmanouilides, C
    Vo, K
    Schilder, RJ
    Foster, P
    Gordon, LI
    Witzig, TE
    Molina, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 607S - 607S
  • [7] Feasibility of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy for non-Hodgkin's lymphoma in a patient with chronic renal failure.
    Spies, SM
    Gordon, LI
    Zimmer, AM
    Cutrera, P
    BLOOD, 2004, 104 (11) : 244B - 244B
  • [8] Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
    Storto, G.
    Nardelli, A.
    Pellegrino, T.
    Perna, F.
    De Falco, T.
    Erra, P.
    Ortosecco, G.
    Castaldi, E.
    Speranza, A.
    Klain, M.
    De Renzo, A.
    di Nuzzo, C.
    Pace, L.
    Rotoli, B.
    Salvatore, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S148 - S148
  • [9] Evaluation of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in patients with non-Hodgkin's lymphoma (NHL) having previously received autologous stem cell transplant (ASCT)
    Jacobs, SA
    McCook, B
    Torok, F
    Avril, N
    Vidnovic, N
    Joyce, J
    Molina, A
    BLOOD, 2004, 104 (11) : 395B - 395B
  • [10] Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Wiseman, GA
    Witzig, TE
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S221 - S221
12345